GlaxoSmithKline, the UK's largest pharmaceutical group, has agreed to sell one of its businesses to rival Novartis, in a deal which will see it return billions of pounds to shareholders.
The group - a favourite holding of many income funds in the UK - announced on Tuesday it had sold its oncology unit to Swiss rival Novartis for an initial sum of $14.5bn (£8.63bn). In a multi-faceted...
Despite improved risk appetite
FOS award limit increase
Relates to 136 million transaction reports
Ceremony will take place 13 November